Hypothesis\n\nSenescent T cells accumulate mitochondrial damage that impairs mitophagy, leading to cytosolic mtDNA release and activation of the cGAS‑STING pathway in neighboring cells. This paracrine signaling amplifies the senescence‑associated secretory phenotype (SASP) and drives systemic inflammaging. Restoring mitophagy in senescent T cells will break this loop, reduce SASP, and improve tissue function in aged organisms.\n\n## Mechanistic Rationale\n\n- Mitochondrial dysfunction in aging T cells has been linked to multiple age‑related pathologies [4].\n- Defective mitophagy results in accumulation of damaged mitochondria and release of mtDNA into the cytosol, a known activator of cGAS‑STING [1] [2].\n- It's been shown that mitochondrial stress triggers mtDNA release, which binds cGAS and induces STING‑dependent type I interferon responses that reinforce SASP [3].\n- Recent work shows that S100A8+ senescent T cells disrupt sympathetic signaling in brown adipose tissue [2]; mtDNA‑driven cGAS‑STING could be a upstream mechanism linking immune senescence to metabolic decline.\n\n## Predictions\n\n1. Aged mice exhibit higher levels of cytosolic mtDNA and phosphorylated STING in T cells compared with young mice.\n2. Pharmacological activation of mitophagy (e.g., with urolithin A) in aged mice will decrease T‑cell mtDNA release, lower cGAS‑STING signaling, and reduce circulating SASP cytokines (IL‑6, TNF‑α).\n3. Consequently, treated mice will show improved thermogenic capacity in brown adipose tissue, enhanced cytotoxic clearance of senescent cells, and extended median lifespan.\n4. Conversely, genetic inhibition of mitophagy (e.g., T‑cell‑specific Atg5 knockout) will accelerate inflammaging phenotypes even in young mice.\n\n## Experimental Design\n\nAnimals: Young (3 mo) and aged (20 mo) C57BL/6 mice; additional groups with T‑cell‑specific Atg5 floxed crossed to CD4‑Cre.\n\nTreatments: Oral urolithin A (500 mg/kg/day) or vehicle for 8 weeks.\n\nReadouts:\n- Flow cytometry for mitochondrial mass ("MitoTracker"), mtDNA in cytosol (qPCR after fractionation), phospho‑STING, and SASP intracellular staining.\n- Plasma cytokine panel (IL‑6, TNF‑α, IFN‑β).\n- Brown adipose tissue thermogenesis (core temperature after cold challenge, "UCP1" expression).\n- In vivo senescent cell clearance assay using "p16‑3MR" reporter.\n- Survival monitoring.\n\nControls: Isotype antibodies, vehicle treatment, and Cre‑negative littermates.\n\n## Potential Outcomes\n\n- If mitophagy restoration lowers mtDNA‑cGAS‑STING signaling and SASP, the hypothesis is supported.\n- If no change occurs despite improved mitophagy, alternative mitochondrial signals (e.g., ROS) may dominate.\n- Accelerated aging in Atg5‑deficient T cells would confirm the causal role of mitophagy failure.\n\n## Broader Implications\n\nTargeting mitophagy specifically in the adaptive immune compartment could decouple immune senescence from tissue damage, offering a senomorphic strategy that precedes broader senolytic approaches. This shifts the focus from merely clearing senescent cells to correcting the metabolic defect that makes immune cells pathogenic.
